News

Insight into Recent Bullish Movements in TMO Options

Insight into Recent Bullish Movements in TMO Options

Understanding Recent TMO Options Activity

Market players are keeping a close eye on the developments concerning Thermo Fisher Scientific (TMO). With significant options trades making headlines, market participants are intrigued by the implications moving forward.

Onlookers should pay attention because when large investments are made, it often signals upcoming changes in the market sentiment related to TMO.

Recently, our tracking revealed noteworthy trades, indicating that both institutional investors and affluent traders are expressing confidence in TMO, or at least making moves that warrant scrutiny.

Today, our options scanner uncovered a total of 14 unique trades in TMO, a figure that clearly indicates heightened activity not typical in routine trading.

The observed trend shows that the mood among these market movers is somewhat split, with 50% taking a bullish stance while 21% appear bearish.

Interestingly, among these trades, 13 consisted of puts valued collectively at about $444,315, and just a single call option priced at $35,800.

Price Target Insights

Upon analyzing the recent trading volumes and Open Interest, it's apparent that the major players are setting their sights on a price target ranging between $520.00 and $570.00 for Thermo Fisher Scientific as the price oscillates in this range over the past three months.

Volume and Open Interest Trends

Monitoring the volume and open interest proves to be a critical strategy in the options trading landscape. This information offers insights into the liquidity and overall interest regarding TMO's options for specific strike prices. An evaluation over the last 30 days reveals the changing patterns of both call and put trades for TMO, particularly within the key price range from $520.00 to $570.00.

30-Day Activity Overview for Thermo Fisher Scientific

Several trades have emerged as noteworthy:

  • Symbol: TMO, Trade Type: PUT, Sentiment: BULLISH, Expiration: 12/20/24, Trade Price: $72.4K
  • Symbol: TMO, Trade Type: PUT, Sentiment: BULLISH, Expiration: 12/20/24, Trade Price: $49.5K
  • Symbol: TMO, Trade Type: PUT, Sentiment: BULLISH, Expiration: 12/20/24, Trade Price: $41.2K
  • Symbol: TMO, Trade Type: CALL, Sentiment: NEUTRAL, Expiration: 01/16/26, Trade Price: $35.8K
  • Symbol: TMO, Trade Type: PUT, Sentiment: NEUTRAL, Expiration: 11/08/24, Trade Price: $31.5K

About Thermo Fisher Scientific

Thermo Fisher Scientific specializes in selling a wide array of scientific instruments and laboratory equipment. Their product range includes diagnostics consumables and life science reagents, categorized into four primary segments: analytical technologies (17%), specialty diagnostic products (10%), life science solutions (23%), and lab products and services, inclusive of CRO services (54%).

Given the unfolding options history surrounding Thermo Fisher Scientific, it becomes vital to examine the overall performance of the company in the current market.

Current Market Performance of Thermo Fisher Scientific

  • Recent trading volume is recorded at 472,526, with TMO experiencing a minor decrease of -0.34%, now priced at $552.47.
  • RSI metrics suggest the stock may be in an oversold position.
  • Investors can expect an earnings announcement in approximately 93 days.

Expert Analyst Ratings for Thermo Fisher Scientific

In the past month, five analysts provided insights on TMO, arriving at an average target price of $637.4. This consensus reflects ongoing confidence in TMO's growth prospects.

Noteworthy Analyst Insights:

Barclays: Maintains Equal-Weight rating, price target at $610.

Evercore ISI Group: Holds Outperform rating with a target of $630.

Wells Fargo: Keeps Overweight rating with a goal of $660.

Stifel: Confirms Buy rating, price target set at $665.

Baird: Sustains Outperform rating with a target of $622.

Options trading presents more risk than traditional stock trading but also offers enhanced profit potential. Serious traders can mitigate these risks through continuous education, diligent monitoring of market indicators, and a disciplined approach to trade management.

Staying ahead in options trading for Thermo Fisher Scientific requires constant updates. Monitoring real-time trades helps investors make informed decisions.

Frequently Asked Questions

What does TMO stand for?

TMO stands for Thermo Fisher Scientific, a major player in the scientific instruments and laboratory equipment market.

Why is there a lot of options activity in TMO?

The increased options activity is often associated with significant market developments and investor sentiment, indicating potential volatility or shifts in price direction.

What do the price targets for TMO suggest?

Analysts suggest a bullish sentiment toward TMO, with average price targets indicating confidence in the company's growth trajectory.

How can I track TMO options trades?

Investors can track options trades via market data platforms that provide real-time insights and analytics on trading volumes and market sentiment.

What should investors consider when trading options?

Options trading requires a comprehensive understanding of market indicators, trade risks, and ongoing market trends to make informed decisions.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

PureHealth's Acid Reflux Solutions: An Investor's Insight

Updated Category News Views 2

Digestive Wellness: The Emerging Opportunity Some days, it feels like everybody's got a gripe about their gut. You nod along at the lunch counter, folks buzzing about digestive this and acid that. But when PureHealth Research pops up with their fancy supplements, well, even the stock market's noisier nonsense starts sounding a bit quieter. They're banking big on the...

Continue Reading
Larry Ellison's Moves Signal Confidence in Oracle's Future

Updated Category News Views 5

Unraveling Ellison's Bold Decision There's nothing like a sudden shift from a tech titan to make Wall Street sit up and take notice. Today, we got the word that Larry Ellison, Oracle's big gun as Executive Chair and CTO, has pulled the plug on his plan to sell Oracle stock. No dice, no distance covered under that plan. And he's made it crystal clear—selling isn't on his...

Continue Reading
D-Wave Faces Legal Questions After CFO Exit and Losses

Updated Category News Views 2

Trouble Brews at D-Wave Quantum Smack in the middle of market chaos, D-Wave Quantum Inc. (NASDAQ: QBTS) seems to have hit a rather gnarly pothole. With disappointing revenue figures for Q2 of 2026—coming in at a measly $3.08 million, far below the expected range of $4.03 million to $4.08 million—investors have more than enough reasons to be irked. When the numbers...

Continue Reading
Countries Eye New Investment Paths at CIFIT 2026

Updated Category News Views 4

Global Investment Winds Shift at CIFIT In the thick of a world that's being turned on its head, you've got big shots from 129 countries and 30 international organizations talking shop at the 26th China International Fair for Investment and Trade (CIFIT) in Xiamen. Take your pick from the 48 of the world's top 50 GDP powerhouses rubbing shoulders there—this ain't your...

Continue Reading
U.S. Green Beret's Mission: Clearing Landmines in Ukraine

Updated Category News Views 1

The Rise of "Safe Ground" on Prime Video This isn't your typical feel-good story—it’s about grit and the unending fight for 'normalcy' where war left scars. Safe Ground, now streaming on Prime Video, showcases Ryan Hendrickson, a U.S. Army Green Beret whose story takes a sharp turn after stepping on an IED in 2010. The day he almost became just another statistic...

Continue Reading
Pizza: The Unlikely Symbol of Universal Togetherness

Updated Category News Views 1

Why Pizza Is More Than Just Food They say a slice of pizza can tell a story. Whether it's a late-night snack amongst college buddies or the centerpiece of a family's Friday tradition, pizza unites like few others can. It morphs from a study aid into a tool for togetherness without skipping a beat, much like a chameleon of the food world. And no one understands this better...

Continue Reading
Damp or Dry: The Battle for Healthy Air in Colorado

Updated Category News Views 4

The Hidden Cost of Colorado's Dry Air Dry climate isn't just a seasonal inconvenience—it's a real hidden cost to living comfortably and healthily in Colorado. With winters colder than a brass monkey's tail and summers that don't offer much relief in terms of humidity, your home's air quality is on the front line. So, what's the financial tale here, and how do you come...

Continue Reading
SystImmune's Data on Iza-bren Show Promise for Lung Cancer

Updated Category News Views 8

Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...

Continue Reading
IASLC Boosts Global Thoracic Cancer Collaboration

Updated Category News Views 3

Breaking Down Barriers in Thoracic Oncology Picture a world where financial walls don't block innovation and knowledge sharing in cancer treatment. The International Association for the Study of Lung Cancer (IASLC) is leading the charge here. They've just launched a new initiative offering complimentary full membership to qualified healthcare professionals in low- and...

Continue Reading
Nocpix Unveils ACE 2 Thermal Riflescope Lineup

Updated Category News Views 9

ACE 2: A Thermal Riflescope That Promises More Let’s dive right into the nitty-gritty of Nocpix’s latest move. On September 12, they launched the ACE 2 Series—the next-gen beast of their flagship thermal riflescope lineup. A step up from the original ACE, this series aims to redefine what hunters can expect from a riflescope, introducing three models: ACE 2 S60R,...

Continue Reading

Top 5 Most Recently Viewed Articles

Combining Forces: Waters Corporation and BD to Lead Diagnostics

Updated Category News Views 331

Exciting Merger in the Life Sciences Sector In a significant move for the life sciences industry, Waters Corporation (NYSE: WAT) has officially announced its plans to merge with BD (Becton, Dickinson and Company) (NYSE: BDX). This merger aims to create a leading entity in the fields of regulated and high-volume testing. The combination is expected to harness the strengths...

Continue Reading
Citius Oncology Strengthens LYMPHIR Launch with New Partnership

Updated Category News Views 109

Citius Oncology Reinforces Distribution for LYMPHIR Citius Oncology, Inc. (Nasdaq: CTOR), a leading company in oncology therapeutics, has taken a significant step by partnering with Cencora, a global provider of pharmaceutical solutions. The newly signed distribution services agreement is aimed at enhancing commercial infrastructure and ensuring the successful launch of...

Continue Reading
Exploring Growth in Low-Code Development Platforms

Updated Category News Views 242

Surging Growth in Low-Code Development Platforms The demand for low-code development platforms is on the rise, with projected growth from USD 26.30 billion in 2025 up to USD 67.12 billion by 2030, at an impressive CAGR of 20.61%. This surge is primarily fueled by organizations adopting hybrid and multi-cloud strategies, making low-code tools essential for modernizing...

Continue Reading
Foresee Pharmaceuticals Unveils Promising Results for Linvemastat

Updated Category News Views 58

Foresee Pharmaceuticals Announces Groundbreaking Phase 1 Results Foresee Pharmaceuticals (TPEx: 6576) is excited to share notable updates regarding its Phase 1 clinical trial of linvemastat (FP-020), a distinctive and selective oral MMP-12 inhibitor. The trial, focused on assessing safety, tolerability, and pharmacokinetics, has been successfully completed and has...

Continue Reading
Unlocking Spring’s Real Estate Potential with Mistoria Group

Updated Category News Views 302

Why May is the Optimal Time for Real Estate Transactions As the weather warms and spring settles in, the real estate market bursts with activity. Leading property experts suggest that May is the prime month to either buy or sell a home. Mish Liyanage, the CEO of Mistoria Group, emphasizes that emerging market trends provide compelling reasons for homeowners and potential...

Continue Reading